Why Bristol-Myers Squibb (BMY) is on investors’ radar

Bristol-Myers Squibb (BMY) has drawn fresh attention after recent trading left the stock down about 5% over the past month and about 8.5% over the past 3 months, despite a positive 1 year total return.

Recent trading has been weaker, with the share price down 2.98% over the past week and 5.03% over the past month. At the same time, the 1 year total shareholder return of 21.32% remains solid, which suggests that momentum has faded in the short term while longer term holders are still ahead.

If you are reassessing your healthcare exposure after Bristol-Myers Squibb’s recent moves, it could be a good moment to widen the lens and check out 32 healthcare AI stocks

With Bristol-Myers Squibb’s share price weaker in recent months, yet a 1 year total return of 21.32% and an indicated intrinsic discount of 55.30%, you have to ask: is this a genuine value opportunity or is the market already factoring in future growth?

Most Popular Narrative: 14.4% Undervalued

According to the most followed narrative, Bristol-Myers Squibb’s fair value of $65 sits above the last close at $55.67, which puts the recent share price weakness into context.

Full-Year 2024 Highlights:

• Total Revenues: $48.3 billion, a 7% increase from 2023.

• GAAP Loss Per Share: $(4.41), compared to earnings of $3.86 in 2023.

• Non-GAAP EPS: $1.15, a significant decrease from $7.51 in 2023.

• Growth Portfolio Revenues: $22.6 billion, a 17% increase, indicating robust performance of newer products.

The narrative leans on a growing new product portfolio, a detailed cash flow view, and a forward earnings framework that together point to a higher long run valuation anchor.

According to Evangelos, this fair value view blends revenue growth assumptions, margin recovery, and a specific earnings multiple that differs from what the market is currently applying.

Result: Fair Value of $65 (UNDERVALUED)

However, this hinges on execution, with pressure from a GAAP loss per share, lower non GAAP EPS, and the possibility that cost saving targets or new launches may be delayed.

Next Steps

Given this mix of concerns and reasons for optimism, use the full data set to pressure test the story yourself and weigh up 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you only stick with what you already own, you risk missing opportunities that better match your goals, risk comfort, and income needs.

• Target resilient income potential by checking out 12 dividend fortresses built around companies offering higher yields with a focus on stability.
• Spot quality at a price that may appeal to you by scanning screener containing 21 high quality undiscovered gems that many investors might not be watching yet.
• Prioritize resilience first and returns second by reviewing 70 resilient stocks with low risk scores designed to highlight companies with lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.